|
Synergistic effect of AGT235 MM and AT1R CC genotypes and classical risk factors in CAD patients and controls |
||||||||
| Classical risk factor |
AGT235 MM |
Whole population1 |
AT1R CC |
Whole population1 |
||||
|
|
||||||||
| Hypertension |
CAD |
Controls |
OR(95%CI) |
CAD |
Controls |
OR(95%CI) |
||
|
|
|
|||||||
| 0 |
0 |
88 |
293 |
1 |
0 |
99 |
334 |
1 |
| 0 |
1 |
18 |
62 |
0.97(0.52–1.78)NS |
1 |
7 |
21 |
1.12(0.42–2.89)NS |
| 1 |
0 |
153 |
130 |
3.92(2.77–5.55)*** |
0 |
182 |
150 |
4.09(2.96–5.66)*** |
| 1 |
1 |
39 |
25 |
5.19(2.88–9.41)*** |
1 |
10 |
5 |
6.75(2.06–23.27)** |
| SI = 1.44; SIM = 1.36; RERI = 1.30; AP = 0.25 |
SI = 1.79; SIM = 1.47; RERI = 2.54; AP = 0.38 |
|||||||
| Smoking |
||||||||
| 0 |
0 |
145 |
315 |
1 |
0 |
177 |
356 |
1 |
| 0 |
1 |
37 |
58 |
1.39(0.86–2.24)NS |
1 |
5 |
17 |
0.59(0.19–1.74)NS |
| 1 |
0 |
96 |
108 |
1.93(1.36–2.75)** |
0 |
104 |
128 |
1.63(1.18–2.27)** |
| 1 |
1 |
20 |
29 |
1.50(0.79–2.85)NS |
1 |
12 |
9 |
2.68(1.03–7.05)* |
| SI = 0.38; SIM = 0.56; RERI = -0.82; AP = -0.55 |
SI = 7.64; SIM = 2.79; RERI = 1.46; AP = 0.54 |
|||||||
| Obesity |
||||||||
| 0 |
0 |
172 |
352 |
1 |
0 |
201 |
394 |
1 |
| 0 |
1 |
42 |
65 |
1.32(0.84–2.07)NS |
1 |
13 |
23 |
1.11(0.52–2.34)NS |
| 1 |
0 |
69 |
71 |
1.99(1.34–2.95)** |
0 |
80 |
90 |
1.74(1.22–2.50)** |
| 1 |
1 |
15 |
22 |
1.40(0.67–2.89)NS |
1 |
4 |
3 |
2.61(0.49–14.83)NS |
| SI = 0.31; SIM = 0.53; RERI = -0.91; AP = -0.65 |
SI = 1.89; SIM = 1.35; RERI = 0.76; AP = 0.29 |
|||||||
| Diabetes |
||||||||
| 0 |
0 |
171 |
396 |
1 |
0 |
201 |
450 |
1 |
| 0 |
1 |
41 |
80 |
1.19(0.77–1.84)NS |
1 |
11 |
26 |
0.95(0.43–2.05)NS |
| 1 |
0 |
70 |
27 |
6.00(3.63–9.98)*** |
0 |
80 |
34 |
5.27(3.34–8.33)*** |
| 1 |
1 |
16 |
7 |
5.29(2.00–14.47)*** |
1 |
6 |
0 |
-- |
| SI = 0.83; SIM = 0.74; RERI = -0.90; AP = -0.17 |
-- |
|||||||
| Dyslipidaemia |
||||||||
| 0 |
0 |
73 |
370 |
1 |
0 |
82 |
424 |
1 |
| 0 |
1 |
14 |
80 |
0.89(0.45–1.71)NS |
1 |
5 |
26 |
0.99(0.32–2.83)NS |
| 1 |
0 |
168 |
53 |
16.07(10.59–24.43)*** |
0 |
199 |
60 |
17.15(11.62–25.37)*** |
| 1 |
1 |
43 |
7 |
31.14(12.81–79.15)*** |
1 |
12 |
0 |
-- |
| SI = 2.01; SIM = 2.18; RERI = 15.18; AP = 0.49 |
-- |
|||||||
|
SI, Rothman's synergy index for interaction; RERI, relative excess risk due to interaction; AP, proportion of disease attributable to interaction; *P < 0.05, **P < 0.005, ***P < 0.0001; 1We performed no further subdivision when analysing these polymorphisms because several classes resulted statistically impossible to analyse due to the reduced number of individuals there included. | ||||||||
Freitas et al. BMC Cardiovascular Disorders 2008 8:15 doi:10.1186/1471-2261-8-15 |
||||||||